-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the State Drug Administration approved the listing of two innovative drugs of Hengrui Medicine
.
So far, Hengrui Medicine has launched 10 innovative drugs
.
.
So far, Hengrui Medicine has launched 10 innovative drugs
.
The two innovative drugs approved by Hengrui Medicine this time are Dulceli Isethionate Tablets and Henggligliflozin Proline, both of which are Class 1 new drugs
.
.
Dalceli is the original CDK4/6 inhibitor.
The approved indication is the combination of fulvestrant for hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative after endocrine therapy.
Treatment of recurrent or metastatic breast cancer
.
The marketing application was included in the priority review and approval procedure by the State Food and Drug Administration in April 2021 according to the breakthrough treatment category
.
As a new and highly selective CDK4/6 inhibitor, Dulceli has innovated the molecular structure of the drug, bringing new treatment options to more HR+/HER2- breast cancer patients
.
The approved indication is the combination of fulvestrant for hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative after endocrine therapy.
Treatment of recurrent or metastatic breast cancer
.
The marketing application was included in the priority review and approval procedure by the State Food and Drug Administration in April 2021 according to the breakthrough treatment category
.
As a new and highly selective CDK4/6 inhibitor, Dulceli has innovated the molecular structure of the drug, bringing new treatment options to more HR+/HER2- breast cancer patients
.
Henggliflozin is a domestically-made innovative SGLT2 inhibitor, used to improve blood glucose control in adult patients with type 2 diabetes
.
In recent years, Hengrui Medicine has made extensive R&D pipeline layout in the field of diabetes.
Hengligliflozin is Hengrui Medicine’s first marketed innovative drug in this field
.
.
In recent years, Hengrui Medicine has made extensive R&D pipeline layout in the field of diabetes.
Hengligliflozin is Hengrui Medicine’s first marketed innovative drug in this field
.
In addition to the 10 innovative drugs that have been marketed, Hengrui Medicine currently has more than 50 innovative drugs under clinical development, and more than 240 clinical trials are being carried out at home and abroad
.
And build a number of technology platforms with independent intellectual property rights, such as proteolytic targeted chimera (PROTAC), fully human antibody library and high-throughput antibody discovery, antibody drug conjugates (ADC), T cell engagers, structure Biology, etc.
, covering the world's cutting-edge technology fields, forming an echelonized product pipeline
.
.
And build a number of technology platforms with independent intellectual property rights, such as proteolytic targeted chimera (PROTAC), fully human antibody library and high-throughput antibody discovery, antibody drug conjugates (ADC), T cell engagers, structure Biology, etc.
, covering the world's cutting-edge technology fields, forming an echelonized product pipeline
.
In addition to the oncology field, Hengrui Medicine also has a comprehensive deployment in the non-oncology field
.
With continuous and high-intensity R&D investment, Hengrui Medicine's talents and scientific research system have become increasingly perfect.
The company has built a large-scale and professional global R&D team of more than 4,500 people, and established a national-level enterprise technology center and post-doctoral scientific research workstation.
, National Molecular Targeted Drug Engineering Research Center, "National Major New Drug Creation" special incubator base and other scientific and technological platforms have laid a solid foundation for the continuous output of high-quality research and development results
.
.
With continuous and high-intensity R&D investment, Hengrui Medicine's talents and scientific research system have become increasingly perfect.
The company has built a large-scale and professional global R&D team of more than 4,500 people, and established a national-level enterprise technology center and post-doctoral scientific research workstation.
, National Molecular Targeted Drug Engineering Research Center, "National Major New Drug Creation" special incubator base and other scientific and technological platforms have laid a solid foundation for the continuous output of high-quality research and development results
.
Sun Piaoyang, Chairman of Hengrui Pharmaceuticals , said that in the new year, Hengrui Pharmaceuticals will continue to maintain a spirit of struggle and pragmatism, constantly adapt to the higher requirements brought by industrial changes, face challenges, seek progress while maintaining stability, and focus on resources.
Innovate, continue to promote internationalization, benefit patients, and benefit people's lives and health
.
Innovate, continue to promote internationalization, benefit patients, and benefit people's lives and health
.
Recently, the State Drug Administration approved the listing of two innovative drugs of Hengrui Medicine
.
So far, Hengrui Medicine has launched 10 innovative drugs
.
.
So far, Hengrui Medicine has launched 10 innovative drugs
.
The two innovative drugs approved by Hengrui Medicine this time are Dulceli Isethionate Tablets and Henggligliflozin Proline, both of which are Class 1 new drugs
.
.
Dalceli is the original CDK4/6 inhibitor.
The approved indication is the combination of fulvestrant for hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative after endocrine therapy.
Treatment of recurrent or metastatic breast cancer
.
The marketing application was included in the priority review and approval procedure by the State Food and Drug Administration in April 2021 according to the breakthrough treatment category
.
As a new and highly selective CDK4/6 inhibitor, Dulceli has innovated the molecular structure of the drug, bringing new treatment options to more HR+/HER2- breast cancer patients
.
The approved indication is the combination of fulvestrant for hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative after endocrine therapy.
Treatment of recurrent or metastatic breast cancer
.
The marketing application was included in the priority review and approval procedure by the State Food and Drug Administration in April 2021 according to the breakthrough treatment category
.
As a new and highly selective CDK4/6 inhibitor, Dulceli has innovated the molecular structure of the drug, bringing new treatment options to more HR+/HER2- breast cancer patients
.
Henggliflozin is a domestically-made innovative SGLT2 inhibitor, used to improve blood glucose control in adult patients with type 2 diabetes
.
In recent years, Hengrui Medicine has made extensive R&D pipeline layout in the field of diabetes.
Hengligliflozin is Hengrui Medicine’s first marketed innovative drug in this field
.
.
In recent years, Hengrui Medicine has made extensive R&D pipeline layout in the field of diabetes.
Hengligliflozin is Hengrui Medicine’s first marketed innovative drug in this field
.
In addition to the 10 innovative drugs that have been marketed, Hengrui Medicine currently has more than 50 innovative drugs under clinical development, and more than 240 clinical trials are being carried out at home and abroad
.
And build a number of technology platforms with independent intellectual property rights, such as proteolytic targeted chimera (PROTAC), fully human antibody library and high-throughput antibody discovery, antibody drug conjugates (ADC), T cell engagers, structure Biology, etc.
, covering the world's cutting-edge technology fields, forming an echelonized product pipeline
.
.
And build a number of technology platforms with independent intellectual property rights, such as proteolytic targeted chimera (PROTAC), fully human antibody library and high-throughput antibody discovery, antibody drug conjugates (ADC), T cell engagers, structure Biology, etc.
, covering the world's cutting-edge technology fields, forming an echelonized product pipeline
.
In addition to the oncology field, Hengrui Medicine also has a comprehensive deployment in the non-oncology field
.
With continuous and high-intensity R&D investment, Hengrui Medicine's talents and scientific research system have become increasingly perfect.
The company has built a large-scale and professional global R&D team of more than 4,500 people, and established a national-level enterprise technology center and post-doctoral scientific research workstation.
, National Molecular Targeted Drug Engineering Research Center, "National Major New Drug Creation" special incubator base and other scientific and technological platforms have laid a solid foundation for the continuous output of high-quality research and development results
.
.
With continuous and high-intensity R&D investment, Hengrui Medicine's talents and scientific research system have become increasingly perfect.
The company has built a large-scale and professional global R&D team of more than 4,500 people, and established a national-level enterprise technology center and post-doctoral scientific research workstation.
, National Molecular Targeted Drug Engineering Research Center, "National Major New Drug Creation" special incubator base and other scientific and technological platforms have laid a solid foundation for the continuous output of high-quality research and development results
.
Sun Piaoyang, Chairman of Hengrui Pharmaceuticals , said that in the new year, Hengrui Pharmaceuticals will continue to maintain a spirit of struggle and pragmatism, constantly adapt to the higher requirements brought by industrial changes, face challenges, seek progress while maintaining stability, and focus on resources.
Innovate, continue to promote internationalization, benefit patients, and benefit people's lives and health
.
Innovate, continue to promote internationalization, benefit patients, and benefit people's lives and health
.
Recently, the State Drug Administration approved the listing of two innovative drugs of Hengrui Medicine
.
So far, Hengrui Medicine has launched 10 innovative drugs
.
.
So far, Hengrui Medicine has launched 10 innovative drugs
.
The two innovative drugs approved by Hengrui Medicine this time are Dulceli Isethionate Tablets and Henggligliflozin Proline, both of which are Class 1 new drugs
.
.
Dalceli is the original CDK4/6 inhibitor.
The approved indication is the combination of fulvestrant for hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative after endocrine therapy.
Treatment of recurrent or metastatic breast cancer
.
The marketing application was included in the priority review and approval procedure by the State Food and Drug Administration in April 2021 according to the breakthrough treatment category
.
As a new and highly selective CDK4/6 inhibitor, Dulceli has innovated the molecular structure of the drug, bringing new treatment options to more HR+/HER2- breast cancer patients
.
The approved indication is the combination of fulvestrant for hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative after endocrine therapy.
Treatment of recurrent or metastatic breast cancer
.
The marketing application was included in the priority review and approval procedure by the State Food and Drug Administration in April 2021 according to the breakthrough treatment category
.
As a new and highly selective CDK4/6 inhibitor, Dulceli has innovated the molecular structure of the drug, bringing new treatment options to more HR+/HER2- breast cancer patients
.
Henggliflozin is a domestically-made innovative SGLT2 inhibitor, used to improve blood glucose control in adult patients with type 2 diabetes
.
In recent years, Hengrui Medicine has made extensive R&D pipeline layout in the field of diabetes.
Hengligliflozin is Hengrui Medicine’s first marketed innovative drug in this field
.
.
In recent years, Hengrui Medicine has made extensive R&D pipeline layout in the field of diabetes.
Hengligliflozin is Hengrui Medicine’s first marketed innovative drug in this field
.
In addition to the 10 innovative drugs that have been marketed, Hengrui Medicine currently has more than 50 innovative drugs under clinical development, and more than 240 clinical trials are being carried out at home and abroad
.
And build a number of technology platforms with independent intellectual property rights, such as proteolytic targeted chimera (PROTAC), fully human antibody library and high-throughput antibody discovery, antibody drug conjugates (ADC), T cell engagers, structure Biology, etc.
, covering the world's cutting-edge technology fields, forming an echelonized product pipeline
.
.
And build a number of technology platforms with independent intellectual property rights, such as proteolytic targeted chimera (PROTAC), fully human antibody library and high-throughput antibody discovery, antibody drug conjugates (ADC), T cell engagers, structure Biology, etc.
, covering the world's cutting-edge technology fields, forming an echelonized product pipeline
.
In addition to the oncology field, Hengrui Medicine also has a comprehensive deployment in the non-oncology field
.
With continuous and high-intensity R&D investment, Hengrui Medicine's talents and scientific research system have become increasingly perfect.
The company has built a large-scale and professional global R&D team of more than 4,500 people, and established a national-level enterprise technology center and post-doctoral scientific research workstation.
, National Molecular Targeted Drug Engineering Research Center, "National Major New Drug Creation" special incubator base and other scientific and technological platforms have laid a solid foundation for the continuous output of high-quality research and development results
.
Tumor Tumor Tumor Talent Talent Talent Enterprise Enterprise Enterprise.
With continuous and high-intensity R&D investment, Hengrui Medicine's talents and scientific research system have become increasingly perfect.
The company has built a large-scale and professional global R&D team of more than 4,500 people, and established a national-level enterprise technology center and post-doctoral scientific research workstation.
, National Molecular Targeted Drug Engineering Research Center, "National Major New Drug Creation" special incubator base and other scientific and technological platforms have laid a solid foundation for the continuous output of high-quality research and development results
.
Sun Piaoyang, Chairman of Hengrui Pharmaceuticals , said that in the new year, Hengrui Pharmaceuticals will continue to maintain a spirit of struggle and pragmatism, constantly adapt to the higher requirements brought by industrial changes, face challenges, seek progress while maintaining stability, and focus on resources.
Innovate, continue to promote internationalization, benefit patients, and benefit people's lives and health
.
Medicine medicine medicine health health health Innovate, continue to promote internationalization, benefit patients, and benefit people's lives and health
.
